Journal ArticleDOI
Radioimmunoguided surgery using the monoclonal antibody B72.3 in colorectal tumors
Brenda J. Sickle-Santanello,Patric J. O'Dwyer,Cathy Mojzisik,Steven E. Tuttle,George H. Hinkle,Michel Rousseau,Jeffrey Schlom,David Colcher,Marlin O. Thurston,Carol Nieroda,Armando Sardi,William B. Farrar,John P. Minton,Edward W. Martin +13 more
Reads0
Chats0
TLDR
The authors have developed a hand-held gamma-detecting probe (GDP) for intraoperative use that improves the sensitivity of external radioimmunodetection and may influence the short-term morbidity and mortality of surgery for colorectal cancer.Abstract:Â
The authors have developed a hand-held gamma-detecting probe (GDP) for intraoperative use that improves the sensitivity of external radioimmunodetection. Radiolabeled monoclonal antibody (MAb) B72.3 was injected in six patients with primary colorectal cancer and 31 patients with recurrent colorectal cancer an average of 16 days preoperatively. The GDP localized the MAb B72.3 in 83 percent of sites. The technique, known as a radioimmunoguided surgery (RIGS) system did not alter the surgical procedure in patients with primary colorectal cancer but did alter the approach in 26 percent (8/31) of patients with recurrent colorectal cancer. Two patients avoided unnecessary liver resections and two underwent extraabdominal approaches to document their disease. The RIGS system may influence the short-term morbidity and mortality of surgery for colorectal cancer. Larger series and longer follow-up are needed to determine whether the RIGS system confers a survival advantage to the patient with colorectal cancer.read more
Citations
More filters
Journal Article
Construction, Binding Properties, Metabolism, and Tumor Targeting of a Single-Chain Fv Derived from the Pancarcinoma Monoclonal Antibody CC49
Diane E. Milenic,Takashi Yokota,David Filpula,M. A. J. Finkelman,S. W. Dodd,James F. Wood,Marc Whitlow,Philip Snoy,Jeffrey Schlom +8 more
TL;DR: The construction and characterization of a recombinant single-chain Fv (sFv) of CC49 was shown to be a Mr 27,000 homogeneous entity which could be efficiently radiolabeled with 125I or 131I and shown to bind biopsies of TAG-72-expressing tumors and may have utility in diagnostic and perhaps therapeutic applications for a range of human carcinomas.
Journal Article
Generation and Characterization of B72.3 Second Generation Monoclonal Antibodies Reactive with the Tumor-associated Glycoprotein 72 Antigen
Raffaella Muraro,Masahide Kuroki,D. Wunderlich,Diane J. Poole,David Colcher,A. Thor,John W. Greiner,Jean F. Simpson,Alfredo A. Molinolo,Philip D. Noguchi +9 more
TL;DR: It is demonstrated that one or more of the anti-TAG-72 CC MAbs may be more efficient than B72.3, or useful in combination with B72,3, toward the further study of human carcinoma cell population and the diagnostic and therapeutic procedures presently utilizing MAb B 72.3.
Journal ArticleDOI
A comprehensive overview of radioguided surgery using gamma detection probe technology
Stephen P. Povoski,Ryan L. Neff,Cathy Mojzisik,David M. O'Malley,George H. Hinkle,Nathan Hall,Douglas A Murrey,Michael V. Knopp,Edward W. Martin +8 more
TL;DR: In the current review, this work has attempted to comprehensively evaluate the history, technical aspects, and clinical applications of radioguided surgery using gamma detection probe technology.
Journal Article
Enhanced Tumor Binding Using Immunohistochemical Analyses by Second Generation Anti-Tumor-associated Glycoprotein 72 Monoclonal Antibodies versus Monoclonal Antibody B72.3 in Human Tissue
TL;DR: Evidence is provided that these second generation anti-tumor-associated glycoprotein MAbs may be more efficient than B72.3 in the further study of human carcinoma cell populations and in the diagnostic and therapeutic procedures presently being pursued with MAb B 72.3.
Journal Article
Characterization and biodistribution of recombinant and recombinant/chimeric constructs of monoclonal antibody B72.3.
David Colcher,Diane E. Milenic,Mario Roselli,Andrew Raubitschek,Geoffrey Yarranton,David J. King,John Robert Adair,Nigel Richard Whittle,Mark Bodmer,Jeffrey Schlom +9 more
TL;DR: A recombinant form of the murine B72.3 as well as a recombinant/chimeric antibody are developed, both of which maintain the tissue binding and idiotypic specificity of the native murine IgG.
References
More filters
Journal ArticleDOI
Use of Radiolabeled Antibodies to Carcinoembryonic Antigen for the Detection and Localization of Diverse Cancers by External Photoscanning
David M. Goldenberg,Frank H. DeLand,E. Edmund Kim,S. Bennett,F J Primus,J.R. van Nagell,N. Estes,P. DeSimone,P. Rayburn +8 more
TL;DR: To determine whether tumors containing carcinoembryonic antigen could be detected by administration of a radiolabeled, affinity-purified, goat lgG, 18 patients with a history of cancer of diverse histopathology received an average total dose of 1.0 mCi of 131l-labeled lGG.
Journal ArticleDOI
A spectrum of monoclonal antibodies reactive with human mammary tumor cells
TL;DR: Eleven monoclonal antibodies were chosen that demonstrated reactivities with human mammary tumor cells and not with apparently normal human tissues, and all five major groups demonstrated binding to human metastatic mammary carcinoma cells both in axillary lymph nodes and at distal sites.
Journal Article
Distribution of Oncofetal Antigen Tumor-associated Glycoprotein-72 Defined by Monoclonal Antibody B72.3
TL;DR: The pancarcinoma distribution and lack of significant reactivity with normal adult tissues of monoclonal antibody B72.3 suggest its potential diagnostic and therapeutic utility for human carcinomas.
Journal ArticleDOI
Tumor localization of radiolabeled antibodies against carcinoembryonic antigen in patients with carcinoma: a critical evaluation.
TL;DR: Purified, [131I]-labeled goat antibodies against carcinoembryonic antigen, which have been shown to localize in human carcinoma in nude mice, were injected into patients with carcinoma and demonstrated that only the anti-CEA antibodies localized in tumors.
Journal ArticleDOI
Results of a 400-patient carcinoembryonic antigen second-look colorectal cancer study.
John P. Minton,James L. Hoehn,David M. Gerber,J. Shelton Horsley,David P. Connolly,Fayiz Salwan,William S. Fletcher,Anatolio B. Cruz,Frank G. Gatchell,Miguel Oviedo,Kenneth K. Meyer,Lasalle D. Leffall,Richard S. Berk,Peter A. Stewart,Susan E. Kurucz +14 more
TL;DR: The highest resectability of recurrent cancer occurred in patients with a CEA level below 11 ng/ml in whom the CEAlevel was determined at intervals of 1 to 2 months.